Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
Prostate-specific antigen testing has not only led to an earlier diagnosis of prostate cancer, but also to an earlier identification of hormone-refractory prostate cancer (HRPC). Many patients identified early with HRPC may receive first-line taxane-based chemotherapy. Patients who progress after first-line chemotherapy are still quite healthy and desire further therapy. No proven treatment options exist for the second-line treatment of HRPC. Finding new agents that are active in the second-line setting and identifying relevant outcome variables and predictive pretreatment variables are crucial in improving survival and quality of life for this patient population.
Rosenberg
Jonathan E
JE
University of California at San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA. jrosenbe@medicine.ucsf.edu
Small
Eric J
EJ
D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel; D008942:Mitoxantrone; D017430:Prostate-Specific Antigen